Across TCGA pan-cancer cohorts, PAXX Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PAXX data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher PAXX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAXX expression acts as an unfavorable survival marker.
SARC are the cancer types where PAXX Mutation most reproducibly stratifies survival.